Empagliflozin Slows Progression of Renal Disease in Diabetes Empagliflozin Slows Progression of Renal Disease in Diabetes
The long-awaited renal outcomes from the EMPA-REG trial with the SGLT-2 inhibitor for type 2 diabetes, empagliflozin indicate that the drug slows progression to kidney disease. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Jardiance | Urology & Nephrology